Related Experiment Video
Updated: Oct 24, 2025

Reconstitution Of β-catenin Degradation In Xenopus Egg Extract
Published on: June 17, 2014
Discovery of an Orally Bioavailable Small-Molecule Inhibitor for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein
Zhen Wang1, Min Zhang1, Victor Quereda1
1Drug Discovery Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612-9497, United States.
Abstract:
Aberrant activation of Wnt/β-catenin signaling is strongly associated with many diseases including cancer invasion and metastasis. Small-molecule targeting of the central signaling node of this pathway, β-catenin, is a biologically rational approach to abolish hyperactivation of β-catenin signaling but has been demonstrated to be a difficult task. Herein, we report a drug-like small molecule, ZW4864, that binds with β-catenin and selectively disrupts the protein-protein interaction (PPI) between B-cell lymphoma 9 (BCL9) and β-catenin while sparing the β-catenin/E-cadherin PPI. ZW4864 dose-dependently suppresses β-catenin signaling activation, downregulates oncogenic β-catenin target genes, and abrogates invasiveness of β-catenin-dependent cancer cells. More importantly, ZW4864 shows good pharmacokinetic properties and effectively suppresses β-catenin target gene expression in the patient-derived xenograft mouse model. This study offers a selective chemical probe to explore β-catenin-related biology and a drug-like small-molecule β-catenin/BCL9 disruptor for future drug development.
Insights
A new drug, ZW4864, targets the Wnt/β-catenin pathway by disrupting the β-catenin/BCL9 interaction. This approach suppresses cancer cell invasion and shows promise for future drug development.
Area of Science:
- Molecular Biology
- Oncology
- Drug Discovery
Background:
- Aberrant Wnt/β-catenin signaling drives cancer invasion and metastasis.
- Targeting β-catenin is a rational strategy, but challenging.
- Selective disruption of protein-protein interactions (PPIs) is an emerging therapeutic approach.
Purpose of the Study:
- To identify and characterize a small molecule that selectively inhibits the Wnt/β-catenin pathway.
- To develop a chemical probe for studying β-catenin biology.
- To provide a potential therapeutic agent for β-catenin-dependent cancers.
Main Methods:
- Small molecule screening and characterization.
- In vitro assays to assess β-catenin signaling inhibition and PPI disruption.
- In vivo studies using patient-derived xenograft mouse models.
- Pharmacokinetic profiling.
Main Results:
- ZW4864 selectively disrupts the β-catenin/BCL9 PPI while sparing the β-catenin/E-cadherin PPI.
- ZW4864 dose-dependently inhibits Wnt/β-catenin signaling and oncogenic gene expression.
- ZW4864 abrogates invasiveness of cancer cells and suppresses tumor growth in vivo.
- ZW4864 exhibits favorable pharmacokinetic properties.
Conclusions:
- ZW4864 is a potent and selective small-molecule inhibitor of the β-catenin/BCL9 interaction.
- This compound effectively suppresses Wnt/β-catenin signaling and cancer cell invasiveness.
- ZW4864 represents a promising drug-like lead for developing novel cancer therapeutics targeting the Wnt pathway.
Related Concept Videos
Catenins
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the...
Inhibition of Cdk Activity
Protein-protein Interfaces

